Substituted pyrrolo[2,3-c][2,7]naphthyridines as CK2 inhibitors
Substituted pyrrolo[2,3-c][2,7]naphthyridines as CK2 inhibitors
-
US 11,884,667 B1
-
الصحة - Health
-
2024
-
مكتب البراءات الأمريكي - US Patent Office
-
Haroun; Michelyne (Al-Ahsa, SA), Tratrat; Christophe (Al-Ahsa, SA)
-
Pyrrolo[2,3-c][2,7]naphthyridine-2-carboxylic acid compounds are provided. The pyrrolo[2,3-c][2,7]naphthyridine-2-carboxylic acid compounds have the general formula: ##STR00001## where R.sub.1 is H, C.sub.1-C.sub.6 alkyl, or C.sub.3-C.sub.6 cycloalkyl, and R.sub.2 is C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 cyanoalkyl, (CH.sub.2).sub.2-3NR.sub.3R.sub.4, (CH.sub.2).sub.1-2aryl, (CH.sub.2).sub.1-2heteroaryl, C(O)—(CH.sub.2).sub.2-3NR.sub.3R.sub.4, C(O)aryl, C(O)heteroaryl, S(O).sub.2—(CH.sub.2).sub.2-3NR.sub.3R.sub.4, S(O).sub.2aryl, S(O).sub.2heteroaryl, C.sub.3-C.sub.6 cycloalkyl, C.sub.3-C.sub.6 halocycloalkyl, C.sub.3-C.sub.6 cyanocycloalkyl, aryl, or 5- or 6-membered heteroaryl. The pyrrolo[2,3-c][2,7]naphthyridine-2-carboxylic acid compounds inhibit protein kinase CK2 activity and may be used as anticancer agents, as well as agents for treating inflammation, pain, immunological disorders, diabetes, viral infections, and neurodegenerative diseases.